Literature DB >> 26404727

Super-Refractory Status Epilepticus.

Mauricio Ruiz Cuero1, Panayiotis N Varelas2,3.   

Abstract

Although the vast majority of patients with status epilepticus (SE) respond fairly well to the first- or second-line anti-epileptics, a minority require anesthetic agents to put the seizures under control. An even smaller number of patients do not even respond to those and constitute the subgroup of super-refractory SE. Because of the small numbers, there are no definitive studies regarding its etiology, pathophysiology, and treatment, and those are still based on expert opinions. Encephalitides, either infectious, autoimmune, or paraneoplastic may be the main etiological factors. Induced pharmacological coma, immunosuppression, electrical brain stimulation, hypothermia, and ketamine are few of the newer but unproven therapeutic approaches that should be considered.

Entities:  

Keywords:  Autoimmune; Barbiturates; Encephalitis; Ketamine; Status epilepticus; Super refractory

Mesh:

Substances:

Year:  2015        PMID: 26404727     DOI: 10.1007/s11910-015-0594-5

Source DB:  PubMed          Journal:  Curr Neurol Neurosci Rep        ISSN: 1528-4042            Impact factor:   5.081


  56 in total

Review 1.  Super-refractory status epilepticus: an approach to therapy in this difficult clinical situation.

Authors:  Simon Shorvon
Journal:  Epilepsia       Date:  2011-10       Impact factor: 5.864

2.  High-dose midazolam therapy for refractory status epilepticus in children.

Authors:  Gavin Morrison; Elizabeth Gibbons; William Patrick Whitehouse
Journal:  Intensive Care Med       Date:  2006-09-15       Impact factor: 17.440

3.  New-onset refractory status epilepticus (NORSE)--The potential role for immunotherapy.

Authors:  Ayaz M Khawaja; Jennifer L DeWolfe; David W Miller; Jerzy P Szaflarski
Journal:  Epilepsy Behav       Date:  2015-05-23       Impact factor: 2.937

Review 4.  Status epilepticus: an update.

Authors:  Panayiotis N Varelas; Marianna V Spanaki; Marek A Mirski
Journal:  Curr Neurol Neurosci Rep       Date:  2013-07       Impact factor: 5.081

5.  Relapse and survival after barbiturate anesthetic treatment of refractory status epilepticus.

Authors:  K B Krishnamurthy; F W Drislane
Journal:  Epilepsia       Date:  1996-09       Impact factor: 5.864

Review 6.  Isoniazid overdose: four case reports and review of the literature.

Authors:  F G Alvarez; K K Guntupalli
Journal:  Intensive Care Med       Date:  1995-08       Impact factor: 17.440

7.  Status epilepticus at an urban public hospital in the 1980s.

Authors:  D H Lowenstein; B K Alldredge
Journal:  Neurology       Date:  1993-03       Impact factor: 9.910

8.  Use-dependent shift from inhibitory to excitatory GABAA receptor action in SP-O interneurons in the rat hippocampal CA3 area.

Authors:  Karri Lamsa; Tomi Taira
Journal:  J Neurophysiol       Date:  2003-05-15       Impact factor: 2.714

9.  Determinants and predictors of outcome in super refractory status epilepticus--a developing country perspective.

Authors:  Sita Jayalakshmi; Devashish Ruikar; Sudhindra Vooturi; Suvarna Alladi; Sambit Sahu; Subhash Kaul; Surath Mohandas
Journal:  Epilepsy Res       Date:  2014-08-30       Impact factor: 3.045

10.  How I treat status epilepticus in the Neuro-ICU.

Authors:  Panayiotis N Varelas
Journal:  Neurocrit Care       Date:  2008       Impact factor: 3.210

View more
  3 in total

Review 1.  Acute Convulsive Seizures: When is It Too Early to Treat?

Authors:  Omar Hussein
Journal:  Perm J       Date:  2019

Review 2.  Updates in Refractory Status Epilepticus.

Authors:  Rohit Marawar; Maysaa Basha; Advait Mahulikar; Aaron Desai; Kushak Suchdev; Aashit Shah
Journal:  Crit Care Res Pract       Date:  2018-05-08

3.  Indications for Inpatient Magnetoencephalography in Children - An Institution's Experience.

Authors:  Michael W Watkins; Ekta G Shah; Michael E Funke; Stephanie Garcia-Tarodo; Manish N Shah; Nitin Tandon; Fernando Maestu; Christopher Laohathai; David I Sandberg; Jeremy Lankford; Stephen Thompson; John Mosher; Gretchen Von Allmen
Journal:  Front Hum Neurosci       Date:  2021-06-04       Impact factor: 3.169

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.